

G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author		
Antiretroviral therapy					
3	P 1	Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in people living with HIV-1 aged over 60 years	Leonardo Calza, Bologna		
.0	P 2	Description of a cohort of people with HIV infection on long-acting antiretroviral therapy	Elisa Gaggero, Genova		
0	P 3	Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as first line regimen in people with HIV: a retrospective observational study	Andrea Giacomelli, Milano		
1	P 4	Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine	Lucia Taramasso, Genova		
2	P 5	Improved lipid profiles in adults living with HIV receiving doravirine-based regimens: week 52 analysis	Neva Braccialarghe, Roma		
4	P 6	Feasibility of cabotegravir and rilpivirine long-acting injection specific program in a large center in Northern Italy: adherence, tolerability and costs	Giorgio Tiecco, Brescia		
.01	P 7	Outdated Antiretroviral Regimens (OLD-ART): A Cross-Sectional Study on the Achilles' Heel of Outpatient Care	Maria Alberti, Brescia		
02	P 8	Experience with the use of prolonged-release injectable CAB/RPV in outpatients	Emanuele Pontali, Genova		
.23	P 9	Cost/effectiveness analysis and assessment of adverse events associated with the administration of the long-acting cabotegravir - rilpivirine association	Davide Cicetti, Bologna		
46	P 10	Unconventional use of Long-Acting CAB+RPV against HIV in PWH in need: real-world data at 48 weeks from an Italian bicentric cohort	Valentina Iannone, Roma		
.53	P 11	Central Nervous System and Neuropsychiatric adverse events in Women Living with HIV treated with INSTI-based regimens	Andrea De Vito, Alghero		
.61	P 12	Switching from 3TC/DTG and RPV/DTG to Triple Drug and Dual PI-Based therapies for toxicity/intolerance: data from the ICONA cohort	Andrea De Vito, Alghero		
.63	P 13	Efficacy and safety of $B/F/TAF$ in na $\~$ ive people with HIV: real life data from the SHiNE and SHiC cohorts	Giulia Moi, Sassari		
209	P 14	Antiretroviral therapy: consumption, costs and demographic profile of patients treated at a University Hospital in Italy in 2023	Lorenzo Martellone, Roma		
211	P 15	Real-life use of doravirine in ART-Experienced PLWH bearing drug resistance mutations: findings from a monocentric cohort study	Sergio Cotugno, Bari		
27	P 16	Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study)	Diego Ripamonti, Bergamo		
233	P 17	Insights into patients perspectives: identifying barriers in the transition from oral to injectable antiretroviral treatment	Mariacristina Poliseno, Bari		
57	P 18	Therapeutic switch to long acting cabotegravir/rilpivirine to overcome malabsorption due to ulcerative colitis in a person living with HIV, a case report	Federico Sabaini, Milano		
63	P 19	High lipid levels in patients living with HIV undergoing triple antiretroviral therapy	Livia Moffa, Chieti		
68	P 20	A real-life study in HIV-infected patients on NNRTI-regimen undergoing therapeutic optimization	Marcello Trizzino, Palermo		
98	P 21	Efficacy and safety of switching to co-formulated DOR/TDF/3TC in HIV-1-infected, ART experienced adults: data from a single Italian Center in Florence, Italy	Giuseppe Formica, Firenze		
05	P 22	Durability of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of treatment-experienced people with HIV: a retrospective observational study	Andrea Rabbione, Milano		



G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author
306	P 23	Durability and effectiveness of dual versus triple INSTI-based antiretroviral therapy in a real-world cohort in Palermo	Roberta Gaudiano, Palermo
311	P 24	Experienced PWH switching to 3TC/TDF/DOR in outpatient setting: real-life data on Lipid changes and ASCVD risk from an Italian multicenter cohort	Valentina Iannone, Roma
315	P 25	Switching to long-acting cabotegravir/rilpivirine: data from an Italian monocentric cohort	Maria Vittoria Cossu, Milano
319	P 26	Changing life perception in a heavy treated population living with HIV after long-acting regimen introduction	Giovanna Picchi, Viterbo
320	P 27	Virological failures in newly discovered people living with HIV treated with TAF/FTC/BIC as first line regimen	Francesco Lamanna, Roma
360	P 28	Treatment experienced PWH switching to 3TC/TDF/DOR: lipid profile changes over 144 Weeks of follow up in a single-center Italian cohort	Valentina Iannone, Roma
363	P 29	Efficacy and tollerability of INI-based 2-drug regime in viro-suppressed patients: a sistematic review and a meta-analysis	Maria Grazia Palamone, Napoli
365	P 30	Switch from Ibalizumab to Lenacapavir in a salvage therapy for a patient with multidrug-resistant HIV infection	Salvatore Martini, Napoli
377	P 31	Optimisation of antiretroviral therapy through a spending review: a population-based approach	Virginia Barchi, Roma
378	P 32	Efficacy and tolerability of long-acting Cabotegravir/Rilpivirine in real-world setting, 52 weeks results	Francescopaolo Antonucci, Foggia
382	P 33	Long-Acting injectable regimen with Cabotegravir + Rilpivirine in people living with HIV: real-life experience from Modena HIV Clinic	Alessandra Soffritti, Modena
385	P 34	Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability	Enrico Morelli, Siena
396	P 35	Preliminary real world experience in a cohort of PLWH undergoing LA CAB/RPV in Latina: a heterogeneous population with homogeneous efficacy and satisfaction	Anna Carraro, Roma
397	P 36	Long-acting injectable antiretroviral therapy: pursuing equity of access through shared decision-making	Elisabetta Teti, Roma
401	P 37	Feasibility of 3TC/DTG as a first-line strategy in the setting of rapid ART initiation: a retrospective study from the Pisan Cohort	Tommaso Matucci, Pisa
409	P 38	Evaluation of resistance-associated mutations to nucleotide reverse transcriptase inhibitors in patients treated with tenofovir disoproxil/lamivudine/doravirine	Damiano Farinacci, Roma
412	P 39	Two is a company: results from a multicenter cohort of PLWHIV starting dolutegravir plus lamivudine as first-line regimen	Arturo Ciccullo, L'Aquila
421	P 40	The Long Acting Therapy with CAB/RPV: experience at the Infectious Diseases Clinic of Perugia $$	Elisabetta Schiaroli, Perugia
426	P 41	Sexual quality of life and genital compartment inflammation in a cohort of patients undergoing long-acting cabotegravir/rilpivirine therapy	Anna Carraro, Roma
427	P 42	Fostemsavir plus doravirine for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multi-drug resistant (MDR) HIV-1 infection: 48 weeks results in a real-life setting	Pierluigi Francesco Salvo, Roma
437	P 43	Incidence of transmitted drug resistance mutations among newly diagnosed HIV $\square 1$ patients: a 6-month retrospective analysis	Michele Cantini, Bologna
450	P 44	Cost-effectiveness of cabotegravir-rilpivirine LA vs. lamivudine/abacavir/dolutegravir and vs. bictegravir/emtricitabine/tenofovir in the treatment of HIV+ patients in Italy, a short-term analysis	Francesco De Nardo, Castellanza VA



A. Cingolani, Roma A. Di Biagio, Genova M. Farinella, Roma G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author	
476	P 45	Carotid Intima Media Thickness is increased in adolescent and young adults living with \ensuremath{HIV}	Marta Stracuzzi, Milano	
477	P 46	20-year review of neurological outcomes in HIV-exposed uninfected children in a pediatric HIV referral center	Marta Stracuzzi, Milano	
Clin	ical HI	V		
7	P 47	Heavily treatment-experienced (HTE) patients with multidrug-resistant HIV infection: population characteristics, treatment strategies, and clinical outcomes	Maddalena Giglia, Bologna	
31	P 48	Factors influencing sleep disorders in people with HIV in a real-life setting	Francesca Alberton, Milano	
45	P 49	An hospital-based integrated Healthy Life Program among PLWH: ongoing data from an outpatients clinic including Infectious Disease specialist, nutritionist, personal trainer and psychologist at "D. Cotugno" hospital, Naples, Italy	Maria Aurora Carleo, Napoli	
55	P 50	Are new lipid lowering agents a good option for achieve lipid goal in HIV subjects?	Raffaele Ferri, Chieti	
59	P 51	100% adherence to ART: a new paradigm in the long-acting era. Data from a cohort in Turin	Gian Carlo Orofino, Torino	
85	P 52	Asymptomatic neurocognitive impairment in People Living With HIV infection (PLWH): are we misdiagnosing for someone?	Benedetto Maurizio Celesia, Catania	
121	P 53	Pregnancy and birth outcomes in women living with HIV: real-life experience	Martina Mazzoccoli, Milano	
135	P 54	Prevalence of sleep disturbance in PLWHA. Time to action	Gian Carlo Orofino, Torino	
136	P 55	Acute cardiac insufficiency in HIV: a jump into the past	Beatrice Fontana, Firenze	
148	P 56	Exploring effectiveness and tolerance: switching to long-acting cabotegravir plus rilpivirine therapy in virologically suppressed individuals with HIV	Claudio Rigamonti, Bologna	
171	P 57	Monitoring quality of life in PLWH using a patient reported outcomes (PRO) and screening tools for emotional and cognitive vulnerability	Massimo Giuliani, Roma	
296	P 58	Peroneal osteomyelitis by Mycobacterium haemophilum in a patient living with HIV	Elena Ghidoni, Modena	
297	P 59	Neutral Metabolic Impact of Long-Acting CAB+RPV in PLWH: A Tuscan Multicenter Observational Study (LAHIV)	Filippo Lagi, Firenze	
299	P 60	Efficacy, safety and discontinuation of rilpivirine and cabotegravir in HIV-1 virologically suppressed adults: a multicenter observational study in Tuscany (LAHIV study)	Filippo Lagi, Firenze	
328	P 61	Salmonella spondylodiscitis and iliopsoas abscesses in a patient with HIV	Antonietta Boccia, Caserta	
334	P 62	Viral blips in patients with Intestinal bowel syndrome (IBS): clinical case observation. Is dolutegravir plus lamivudine sufficiently protective against the risk of viral escape?	Marco Di Gregorio, Brescia	
379	P 63	Prospective Memory and antiretroviral medication adherence in HIV	Valentina Massaroni, Roma	
393	P 64	MULTicentric HIV patients tracer For clinicAl assistanCe and rEsearch: feasibility, preliminary data from the MULTIFACE study	Federico Frondizi, Roma	
435	P 65	Exploring potential interactions between intramuscular cabotegravir(CAB)/rilpivirine (RPV) and methadone: a case report	Pierluigi Francesco Salvo, Roma	
442	P 66	Patients' attitudes towards telehealth for HIV care: a single center survey	Lolita Sasset, Padova	
Cooperation projects in low income countries				
41	P 67	Prevalence of water-borne diseases among people exposed to climate disasters in Mozambique: a cross-sectional study	Francesco Di Gennaro, Bari	
Epid	lemiol	ogy of viral infections		
22	P 68	Recent infections in new HIV diagnoses: results of the national surveillance system	Lucia Pugliese, Roma	



G. C. Marchetti, Milano









Elenco Poster

ID	N.pgm	Title	Presenting Author
207	P 69	Applications of excess event estimation to investigate mortality and infection spread during the covid19 pandemic	Luigi Palla, Roma
208	P 70	Back to the measles – first evidence of viral circulation in Liguria, Northern Italy, 2024	Giada Garzillo, Genova
314	P 71	Short-term mortality in people with HIV infection over the past two decades	Monica Melchio, Genova
391	P 72	HIV screening and treatment in two penitentiaries in Northern Italy: a retrospective analysis	Anna Cambianica, Brescia
395	P 73	Clinical and Epidemiological Insights in Severe Influenza patients admitted to emergency department with respiratory symptoms in the fourth year of SARS-CoV-2 pandemic	Alberico Parente, Latina
428	P 74	The changing landscape of hospitalized PLWH: how the referral of cases in a center Italy ward changed during the SARS-CoV-2 pandemic	Francesco Pallotta, Macerata
HIV	coinfe	ctions and comorbidities	
80	P 75	Weight gain and lipid change according to baseline comorbidities and previous antiretroviral regimen in cohort of people treated with bictegravir/emtricitabine/tenofovir alafenamide	Lucia Taramasso, Genova
93	P 76	Multidimensional characterization of erectile dysfunction in young man living with HIV: a cross-sectional study	Giorgio Tiecco, Brescia
106	P 77	The influence of blood brain barrier permeability on serum-to-CSF ratios of central nervous system biomarkers in people with HIV	Jessica Cusato, Torino
125	P 78	Nutrition support service focused on weight loss in an HIV outpatient clinic: our experience	Paola Vitiello, Busto Arsizio VA
139	P 79	High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH)	Nicola Squillace, Monza
144	P 80	Challenging the Bounds of Co-Infection: A Case Study on Severe Monkeypox in an Untreated HIV Patient and the Role of Tecovirimat in Treatment Efficacy	Tosca Semenzin, Udine
150	P 81	Risk factors associated with NAFLD in people living with HIV	Valeria Brogna, Monza
173	P 82	Correlation between lipid profile, subclinical atherosclerosis, hepatic fibrosteatosis, and bone mineral density in PLWH: comparison between TAF/FTC/BIC and TDF/3TC/DOR	Valentina Iodice, Caserta
217	P 83	Incidence of lung-cancer in a cohort of PWH: a retrospective single-center observational study	Giorgia Carrozzo, Milano
224	P 84	Prevalence, characteristics and outcomes of TB-IRIS among a cohort of PWH and TB	Lorenzo Crupi, Genova
229	P 85	Correlation among bone, endothelial and hepatic damage in PLWH	Addolorata Masiello, Caserta
237	P 86	Extrapulmonary TB diagnosed during cabotegravir/rilpivirine long acting therapy: a novel pharmacologic challenge	Giovanna Picchi, Viterbo
286	P 87	Bulevirtide: Treatment in people living with HIV	Layla Pagnucco, Pavia
310	P 88	Influence of AIDS-defining events on PLWH hospitalization: implications for DRGs and length of stay. A retrospective administrative data analysis	Gabriele Cavazza, Milano
312	P 89	Prevalence of metabolic syndrome among PLWH assuming NVP containing regimens and INSTI based dual therapy	Federico Conti, Lecco
333	P 90	Plasma markers of gastrointestinal mucosal barrier dysfunction in PLWH receiving cART	Valentina Artusa, Milano
344	P 91	Characterization of bacterial infections in people living with HIV from January 2018 to January 2023	Chiara Nonne, Roma



G. C. Marchetti, Milano

16° CONGRESSO NAZIONALE Italian Conference on AIDS and Antiviral Research





RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author
369	P 92	Severe Neurological Manifestations and Medication Challenges in an Elderly Female Cancer Patient: a missed opportunity	Livia Bresciani, Milano
375	P 93	Experience of collaboration between a PLWH Clinic and a clinical nutrition centre at a hospital in the north-east of Italy	Giuliana Battagin, Vicenza
387	P 94	NK cell profile in the anal mucosa of MSM living with HIV: results from a single center clinical trial	Letizia Santinelli, Roma
392	P 95	Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV	Francesca Panza, Siena
402	P 96	CNS-associated VZV vasculopathy in a young woman living with HIV	Virginia Maria Vitaletti, Milano
414	P 97	Exploring cardiovascular risk in people with HIV: the critical role of intima-media thickness	Michele Salvatore Paternò Raddusa, Catania
455	P 98	Periaortic BCGite in HIV	Lorenzo Abbate, Bologna
456	P 99	Poor sleep quality in people living with HIV	Layla Pagnucco, Pavia
479	P 100	Epicardial adipose tissue is increased in HIV infected adolescent and young adults	Marta Stracuzzi, Milano
Imn	nunopa	athogenesis	
104	P 101	Auto-antibodies neutralizing type I and III IFNs in patients with WNV infection	Federica Frasca, Roma
279	P 102	HIV acquisition at birth does not drive T-cell dysfunction in Heavily Treatment Experienced (HTE): data from the Prestigio Registry	Valeria Bono, Milano
291	P 103	Multidrug resistance is associated with different gene methylation in people with HIV: a matched cohort study with data from the PRESTIGIO Registry	Tommaso Clemente, Milano
374	P 104	HIV latency is associated with changes in the Wnt1, $\beta\text{-catenin},$ TGF- β and BCL-2 signalling pathways	Luca Maddaloni, Roma
399	P 105	Is CAB/RPV-LA able to modulate residual immune activation in people living with HIV? A pilot single-arm longitudinal study	Maria Antonella Zingaropoli, Roma
415	P 106	Higher IP-10 values correlate with a viral cause of infection: a retrospective study based on novel tests	Blerta Kertusha, Latina
Oth	er infe	ctions in the immunocompromised host	
119	P 107	Cytomegalovirus specific T-cell response in people with multiple sclerosis under different disease-modifying therapies	Federica Dominelli, Roma
349	P 108	Aspergillus spp infection in immunocompromised and non-neutropenic patients in Infection Intensive Care: a retrospective observational study	Dorotea Rubino, Roma
372	P 109	Multidrug resistant bacteria (MDRB) and bed turnover: is it true that the fragile patient should be moved the least possible?	Chiara Fanelli, Sassari
400	P 110	Evaluation of HHV6 reactivation in gastric biopsy and blood samples in patients underwent allogeneic stem cell transplant (HSCT) for hematological malignancies: results from a retrospective single center analysis	Giuseppina Colomba, Palermo
452	P 111	Challenges in an Immunocompromised Host: A Case of Disseminated Nocardiosis	Andrea Gizzi, Palermo
SAR	S-CoV	-2 infection and long COVID	
38	P 112	SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43	Micaela Garziano, Milano
47	P 113	Use of combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab in an immunocompromised patient with persistent severe SARS-CoV-2 acute respiratory syndrome	Gisella D'Aguanno, Marsala TP



A. Cingolani, Roma A. Di Biagio, Genova M. Farinella, Roma G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author
53	P 114	Exploring Early COVID-19 Therapies, Variants, and Viral Clearance Dynamics: Insights from a High-Risk Outpatients Study	Maddalena Matone, Milano
186	P 115	Characteristics of Long COVID after two years of follow-up in a previously hospitalized population	Viola Cogliandro, Monza
248	P 116	The evolving landscape of COVID-19: Characteristics and factors associated with disease severity and mortality in recent hospitalisations	Drieda Zace, Roma
266	P 117	Prolonged combination treatment: an efficient and safe strategy for managing SARS-CoV-2 infection in immunocompromised patients	Chiara Sepulcri, Genova
406	P 118	Cytomegalovirus reactivation in non-severe COVID-19: two emblematic cases of oropharyngeal mucositis in immunocompromised patients	Roberta Astorri, Napoli
407	P 119	Combination therapy in immunocompromised patients with COVID-19	Francesco Rosario Paolo Ieva, Foggia
480	P 120	Sex disparity in COVID infection: a retrospective study using serum electrophoretic analysis (SPE) in men and women infected by COVID-19	Flaminia Tomassetti, Roma
Sex	ually t	ansmitted infections	
24	=	Anorectal lesions: think twice	Viola Gennaro, Torino
77	P 122	The use of pre-exposure prophylaxis (PrEP) in the control of HIV infection and other sexually transmitted diseases (STDs). Descriptive-observational analysis in an italian polyclinic	Davide Cicetti, Bologna
86	P 123	Screening of sexually transmitted diseases: experience from Galliera hospital in Genoa	Roberta Prinapori, Genova
92	P 124	A case of secondary syphilis with pulmonary involvement in a person living with HIV	Federica Guida Marascia, Palermo
204	P 125	Long distances for STI care. The case of the an ambulatory service in Bari	Luigi Ronga, Bari
241	P 126	Meeting on HIV and sexually transmitted infections in a high school in Palermo, Italy	Luca Pipitò, Palermo
285	P 127	Sexual behaviour and age related incidence of sexually transmitted infections in PrEP's users	Francesco Romano, Roma
288	P 128	Prevalence of sexually transmitted infections in cisgender women coming to walk-in Center	Gaia Catalano, Milano
300	P 129	Molecular assay-based extragenital screening for Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men	Rebecca Jo Steiner, Roma
329	P 130	M. genitalium macrolide and fluoroquinolone resistance in Ce.Mu.S.S. Cohort: a descriptive monocentric report	Marco Tutone, Torino
357	P 131	Emerging Sexually Transmitted Infections Outbreak: Dermatophytosis among Men who Have Sex with Men in Milan, Italy	Chiara Maci, Milano
425	P 132	Implementing anal cancer screening in gay and bisexual men who have sex with men starting from a community-based setting	Eugenio Nelson Cavallari, Roma
460	P 133	Syphilis among PLWH: prevalence of the infection in relation to COVID-19 outbreak	Roberta Campagna, Roma
465	P 134	This goes out to the underdog: how not to neglect sexually transmitted infections	Alessandro Tili, Modena
474	P 135	A case of syphilitic vitritis with complicated course	Federica Ceriegi, Pisa
Soci	ial and	behavioural science, marginalized groups, community aspects and com	munity surveys
4		Long Acting Therapy: what PLWHIV think about it	Sandro Mattioli, Bologna
14		Stigma and disinformation are still common in population approaching the Anlaids Forum	Alberto Venturelli, Piacenza



A. Cingolani, Roma A. Di Biagio, Genova M. Farinella, Roma G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author
16	P 138	Cosa sai di Hiv e altre IST	Bruno Marchini, Lodi
18	P 139	Home delivery of ARV and HIV self-tests	Mario Cascio, Milano
23	P 140	Promoting Sexual Health Equity: A Community Engagement Model for Minor Ethnic Groups in Italy	Ifeoma Nneka Emelurumonye, Reading UK
30	P 141	HIV prevention road map	Brunella Mocci, Cagliari
46	P 142	Ongoing psycho-social interventions: preliminary data of the "FRAGIL/mente" project	Angela Calluso, Bari
48	P 143	Stigma and HIV. Perceptions in young people from Anlaids School	Rosario Galipò, Roma
56	P 144	Adherence to HIV infection care at IRCCS San Raffaele Hospital: current status and Re-stART project	Diana Canetti, Milano
60	P 145	Knowledge about Sexually Transmitted Infections and HIV awareness in an Italian adolescent and young adults group	Sara Tordi, Perugia
67	P 146	"What we wanted was what we needed" - rebuilding a community of memories and inclusive advocacy for emerging hepatitis C research via a community-led multilingual documentary production	Rocco Pignata, Bruxelles BE
70	P 147	HIV Tutor Care service at "D. Cotugno" hospital in Naples: a cooperative model between Public Institutions and Community Associations for the improving of well-being among Persons With HIV	Carlo Oneto, Napoli
71	P 148	School intervention for STIs prevention	Chiara Soligo, Milano
74	P 149	Impact of social determinants of health on adherence rate to antiretroviral therapy in the clinical setting	Greta Maffeis, Torino
91	P 150	Noi, donne	Daria Russo, Milano
98	P 151	Assessment of comprehensive sexuality education: a framework of indicators to evaluate interventions in Italian secondary schools	Domenico Martinelli, Foggia
100	P 152	Understanding and managing new HIV diagnoses in members of "generation Z" (1996 -2010) in Milan, Italy: project GenZ HIV-support	Giorgio Bozzi, Milano
122	P 153	PEP/PrEP for Bacterial STIs and HIV-PrEP: knowledge and use among MSM in Rome	Alessandra Latini, Roma
129	P 154	Proactive testing for sexually transmitted and endemic diseases at an open access clinic for migrants	Riccardo Ligresti, Milano
151	P 155	An alliance in communication: LILA training for journalists	Giacomo Dessi, Como
174	P 156	Chemsex, sexualized drug use and emotional vulnerability among MSM of a pilot survey of an STI/HIV center	Stella Capodieci, Roma
178	P 157	Go-come back-cure for HCV management: the role of the continuos presence of the infectious disease (ID) specialist at public health services dedicated to the assistance of addicted subjects (SerD) in Italy	Elena Rastrelli, Viterbo
214	P 158	HIV prevention in the high schools of Sardinia: the experience of LILA Cagliari	Giacomo Dessi, Como
238	P 159	Access to healthcare by Transgender and Gender Non-conforming individuals: preliminary evidence from a cross-sectional study	Federico Fama, Milano
250	P 160	ReTe AIDS: shared telephone counselling strategies to meet people's information needs on STIs	Anna Colucci, Roma
261	P 161	Specialized clinic experience at the Multidisciplinary Center for Sexual Health (Ce.Mu.S. S) in Turin for managing female genital mutilation victims: an integrated approach	Anita Fortunato, Torino
295	P 162	Bridging gaps in HIV screening for marginalized communities: insights from a community-based center in Genoa, Italy	Gloria Notore, Genova



A. Cingolani, Roma A. Di Biagio, Genova M. Farinella, Roma G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author
301	P 163	Problematic chemsex: a multidisciplinary approach	Giorgia Fracca, Milano
309	P 164	Italian parents and teachers' attitudes and perceptions of a comprehensive sexuality education activity in secondary schools: the EduForIST national project	Alice Chinelli, Pisa
330	P 165	Association between emotional reactivity and Internalized Stigma among People Living with HIV	Valentina Massaroni, Roma
361	P 166	The health and care needs of women living with HIV today: a cross-sectional analysis	Chiara Picarelli, Roma
389	P 167	The use of Lorenz Curves and Gini index for the evaluation of HIV viral load distribution in the community	Stefania Arsuffi, Brescia
422	P 168	Mono symptomatic therapeutical group for chemsex addiction to MDPV	Giorgia Fracca, Milano
431	P 169	How relevant is working with key populations?	Davide Meli, Chiuduno BG
436	P 170	Sleep disorders in People Living with HIV in integrase-inhibitors based regimen	Damiano Farinacci, Roma
443	P 171	Impact of the Italian campaign "U=U: impossibile sbagliare" on people with HIV housed in CICA's network accommodation	Laura Amelia Rachele Rancilio, Milano
453	P 172	Better questions, deeper conversation. Blood donation among the LGBTQIA+ community: a gender-neutral survey	Isabella Banchini, Bologna
Test	ing, p	revention and PrEP: clinical perspectives and community best practice	
15	P 173	Appropriateness and strategic value of Post-Exposure Prophylaxis (PEP) for HIV today: experience from an Infectious Diseases referral centre, March-December 2023, Italy	Francesco Maria Fusco, Napoli
52	P 174	Two years analysis of COBATEST data in Ancona Checkpoint and our experience of "tele visita PrEP"	Sara Caucci, Ancona
87	P 175	"TelePrEP" – A pilot program for the delivery of remote PrEP services	Sabrina Penon, Milano
88	P 176	Testing for HIV in CBVCT services adhering to the COBATEST Network - 2020-2023	Maria Luisa Cosmaro, Milano
183	P 177	Sexual assault is associated to loss to follow-up for non-occupational Post-Exposure Prophylaxis for HIV	Arianna Liparoti, Milano
252	P 178	Evaluating tolerance and safety profiles of Pre-Exposure Prophylaxis (PrEP) for HIV: insights from renal and hepatic function monitoring	Gianluca Cuomo, Modena
272	P 179	Renal toxicity in a cohort of PrEP users	Laura Labate, Genova
338	P 180	Outreach programme in sex-on-premises venues: facilitating linkage to care and prevention services	Paolo Marco Testoni, Milano
341	P 181	Alteration of transaminases in PrEP users: investigation of possible causal factors other than $\ensuremath{FTC/TDF}$	Chiara Fusetti, Milano
350	P 182	UniversiTest: peer to peer approaching. Informing and Testing	Mariangela Niglio, Foggia
358	P 183	Two and a half years of In- and Out-Hospital counselling and testing activities: two different and comprehensive preventive strategies	Giulia Mancarella, Latina
390	P 184	HIV drug resistance test harbouring the RT M184V mutation in a PrEP (Pre Exposure Prophylaxis) administered sex worker	Valeria Micheli, Milano
424	P 185	Implementation of a provincial PrEP clinic: analysis by public refundability and new HIV infection diagnoses in Latina $$	Anna Carraro, Roma
433	P 186	Differentiated and simplified PrEP delivery in Italy: alignment with WHO guidance is needed	Pietro Leone Giovanni Vinti, Milano
449	P 187	Evaluation of injectable long acting cabotegravir as response to oral PrEP-related medical issues	Roberto Rossotti, Milano



nnnn/nnnn

G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author				
471	P 188	Sexual habits and STDs occurrence in people attending a new PrEP clinic in Brescia	Davide Minisci, Brescia				
Vac	cines						
58	P 189	Strategies based on nudging to reduce vaccine hesitancy in PLWHA in a northern Italy center	Gian Carlo Orofino, Torino				
79	P 190	Vaccine uptake pre and post COVID-19 pandemic among PLWH	Elisa Suardi, Milano				
99	P 191	A systematic and evidence-based approach in vaccination of people living with HIV: the Notebook of Clinical Vaccinology	Piera Amoriello Lamberti, Roma				
105	P 192	Antibody and Interferon response in HIV patients following mRNA-based SARS-CoV-2 vaccine	Alessandra D'Auria, Roma				
107	P 193	Evaluation of functional antibodies against HIV Env and Tat proteins: analysis of antibody-dependent cell-mediated cytotoxicity (ADCC)	Mara Martino, Ferrara				
118	P 194	Correlation between immune response and adverse events in MS patients after Shingrix vaccine administration	Ilenia Fato, Roma				
138	P 195	Evaluation of cell-mediated Immunity to HPV nonavalent vaccine (Gardasil9 \otimes) in a cohort of people living with HIV	Lorenzo Ansaldo, Latina				
142	P 196	PrEP access highlights worrisome gap in vaccination coverage against HPV and other vaccine preventable STIs	Rebecca Fattore, Milano				
198	P 197	Lactoferrin assumption in vaccinated subjects infected by Sars-CoV-2 may influence time length of negativization	Gaetana Costanza, Roma				
221	P 198	Analysis of Spike-specific immunity induced by IDLV-Spike in mice: comparison between females and males	Alessandra Gallinaro, Roma				
281	P 199	Neutralizing antibodies titers against ten viral Spike protein variants of SARS-CoV-2 in the serum of patients receiving dialysis before and 30 days after the XBB1.5 updated mRNA vaccination	Giuseppe Lipari, Milano				
282	P 200	Neutralizing antibody response to the highly divergent BA.2.86 SARS-CoV-2 lineages in vaccinated health care workers with or without subsequent infection	Ilenia Varasi, Siena				
290	P 201	Hepatitis A virus protection status in cis males and transgender females who live with HIV and have sex with men: a retrospective observational study	Serena Reato, Milano				
331	P 202	Beyond the barriers: the impact of HPV vaccination program variation among MSM PLWH	Miriam Inverardi, Brescia				
373	P 203	Varicella Zoster Virus Vaccination in immunocompromised patients with haematological and rheumatological diseases: specific T-cell response measured with an in-house Interferon Gamma Release Assay	Luigi Coppola, Roma				
417	P 204	Behavioral and epidemiological survey on compliance to receive new booster doses of anti-SARS-Cov2 vaccine in PLWH	Giulia Del Duca, Roma				
440	P 205	Specific T-cell responses to Varicella Zoster Virus glycoprotein E one year after vaccination with a recombinant adjuvanted subunit vaccine in people with multiple sclerosis on disease modifying treatments	Marco Iannetta, Roma				
Vira	Viral hepatitis						
131	P 206	Risk of HBV reactivation and loss of anti-HBc in anti-CD20 treated multiple sclerosis patients: a six-year observational cohort study	Yann Collins Fosso Ngangue, Roma				
175	P 207	Bulevirtide for the treatment of hepatitis D: a case series	Francesco Caruso, Milano				
230	P 208	HBs isoforms as innovative biomarkers in predicting virological response in chronic hepatitis delta patients treated with bulevirtide monotherapy	Stefano D'Anna, Roma				



A. Cingolani, Roma A. Di Biagio, Genova M. Farinella, Roma G. C. Marchetti, Milano







RESEARCH and CARE: FROM BENCH, TO BEDSIDE, TO COMMUNITY

Elenco Poster

ID	N.pgm	Title	Presenting Author
236	P 209	First case of hepatitis B virus (HBV) reactivation in a patient with breast cancer receiving CDK4/6 inhibitor drugs	Francesco Capriotti, Parma
253	P 210	Bulevirtide effectiveness and safety in cirrhotic and non cirrhotic patients in Sardinia	Anna Antonella Mariani , Sassari
337	P 211	Hepatitis delta testing in adults with chronic hepatitis B virus infection attending for outpatient care: Who are those unscreened?	Andrea Di Lorenzo, Roma
403	P 212	Dengue associated hepatitis: two case reports and literature review	Blerta Kertusha, Latina
458	P 213	HBV reactivation after immunosuppressive therapy: an open question	Michelle Abbott, Palermo
478	P 214	Natural history and management Pediatric HCV: 25 years experience of North Italian center	Francesca Musto, Milano
Viro	logy a	nd pharmacology	
89	P 215	Optimization of HIV-1 Next Generation Sequencing genotyping drug resistance testing methods from both RNA and DNA on Ion GeneStudio S5 prime System	Lavinia Fabeni, Roma
97	P 216	Evaluation of broad-spectrum piperazine-based compounds able to inhibit flavivirus and/or SARS-CoV-2 replication in a live virus assay	Camilla Biba, Siena
103	P 217	Idiosyncratic drug liver injury during long-acting HIV treatment: A Case Report	Lorenzo Brando Lundgren, Milano
112	P 218	Comparative evaluation of 5 RT-PCR kits for Dengue virus detection	Chiara Fraccalvieri, Genova
115	P 219	Success rate of HIV DNA Sanger sequencing in PBMC and whole blood samples	Tiziano Giacomo Allice, Torino
172	P 220	Effects of DTG in cardiovascular system development in a model of zebrafish embryo	Cosimo Colangelo, Brescia
200	P 221	HIV-DNA quantification as prediction of GRT success in HIV-DNA NGS	Federica Stefanelli, Genova
256	P 222	Erdosteine inhibits viral infection and modulates innate immunity and stress oxidative state in RSV-infected A549 cells	Sergio Strizzi, Milano
404	P 223	Comparison of Sanger sequencing and amplicon-based NGS approaches for the detection of HIV-1 drug resistance mutations	Lia Fiaschi, Siena
438	P 224	Depth coverage and HIV-1 variability negatively affect the performance of the "HIV-1 solution $v2"$ NGS sequencing kit for drug resistance monitoring	Francesco Saladini, Siena
462	P 225	Case report on the effect of antiretroviral treatment on a young man with uncertain HIV diagnosis, immune dysfunction and high expression of HERVs	Claudia Matteucci, Roma